Valuation: PFIZER

Market Cap 16TCr 16TCr 14TCr 14TCr 12TCr 23TCr 15,70800Cr 23TCr 1,64000Cr 63TCr 8,02100Cr 61TCr 60TCr 25,81200Cr P/E 2026 *
18.1x
P/E 2027 * 14x
Enterprise Value 21TCr 21TCr 19TCr 18TCr 16TCr 30TCr 20,26400Cr 30TCr 2,11500Cr 82TCr 10,34800Cr 79TCr 78TCr 33,29900Cr EV / Sales 2026 *
3.39x
EV / Sales 2027 * 3.42x
Free-Float
59.05%
Yield 2026 *
5.99%
Yield 2027 * 6.04%
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 55 16/08/2026
Compliance Officer 65 01/12/2013
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.32%+1.01%+62.70%+120.06% 1,05600Cr
-1.71%-0.82%+46.99%+71.41% 66TCr
-1.00%-0.66%+18.06%+76.75% 47TCr
-1.72%-4.06%+36.39%+39.47% 34TCr
-0.40%+3.83%+22.08%+28.82% 28TCr
-0.51%-1.93%+12.09%+11.94% 26TCr
+0.34%+2.43%+53.38%+56.36% 23TCr
-1.01%-1.20%+33.94%+101.29% 19TCr
-0.24%-2.76%-28.41%-60.92% 17TCr
Average -0.73%+0.97%+28.58%+49.46% 40.48TCr
Weighted average by Cap. -0.79%+1.04%+38.66%+70.22%

Financials

2026 *2027 *
Net sales 6.22TCr 6.22TCr 5.49TCr 5.2TCr 4.71TCr 8.84TCr 5,97200Cr 8.92TCr 62TCr 24TCr 3,05000Cr 23TCr 23TCr 9,81300Cr 5.98TCr 5.98TCr 5.27TCr 4.99TCr 4.53TCr 8.48TCr 5,73500Cr 8.57TCr 60TCr 23TCr 2,92900Cr 22TCr 22TCr 9,42400Cr
Net income 890.05Cr 890.05Cr 785.47Cr 743.17Cr 673.98Cr 1.26TCr 85TCr 1.28TCr 8.92TCr 3.44TCr 44TCr 3.34TCr 3.27TCr 1,40300Cr 1.11TCr 1.11TCr 977.83Cr 925.17Cr 839.04Cr 1.57TCr 1,06300Cr 1.59TCr 11TCr 4.28TCr 54TCr 4.16TCr 4.07TCr 1,74700Cr
Net Debt 4.75TCr 4.75TCr 4.19TCr 3.96TCr 3.6TCr 6.74TCr 4,55600Cr 6.81TCr 48TCr 18TCr 2,32700Cr 18TCr 17TCr 7,48700Cr 4.1TCr 4.1TCr 3.62TCr 3.42TCr 3.1TCr 5.82TCr 3,93200Cr 5.88TCr 41TCr 16TCr 2,00800Cr 15TCr 15TCr 6,46200Cr
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A